Kümmel A, Kümmel S, Barinoff J, Heitz F, Holtschmidt J, Weikel W, Lorenz-Salehi F, du Bois A, Harter P, Traut A, Blohmer J U, Ataseven B
Klinik für Gynäkologie & Gynäkologische Onkologie, Kliniken Essen-Mitte, Essen.
Geburtshilfe Frauenheilkd. 2015 Jul;75(7):710-718. doi: 10.1055/s-0035-1546050.
The risk of recurrence in breast cancer depends on factors such as treatment but also on the intrinsic subtype. We analyzed the risk factors for local, loco-regional and systemic recurrence, evaluated the differences and analyzed the risk of recurrence for different molecular subtypes. A total of 3054 breast cancer patients who underwent surgery followed by adjuvant treatment at HSK hospital or Essen Mitte Hospital between 1998 and 2011 were analyzed. Based on immunohistochemical parameters, cancers were divided into the following subgroups: luminal A, luminal B (HER2-), luminal B (HER2+), HER2+ and TNBC (triple negative breast cancer). 67 % of tumors were classified as luminal A, 13 % as luminal B (HER2-), 6 % as luminal B (HER2+), 3 % as HER2+ and 11 % as TNBC. After a median follow-up time of 6.6 years there were 100 local (3.3 %), 32 loco-regional (1 %) and 248 distant recurrences (8 %). Five-year recurrence-free survival for the overall patient collective was 92 %. On multivariate analysis, positive nodal status, TNBC subtype and absence of radiation therapy were found to be independent risk factors for all forms of recurrence. Age < 50 years, tumor size, luminal B (HER2-) subtype and breast-conserving therapy were additional risk factors for local recurrence. Compared to the luminal A subtype, the risk of systemic recurrence was higher for all other subtypes; additional risk factors for systemic recurrence were lymphatic invasion, absence of systemic therapy and mastectomy. Overall, the risk of local and loco-regional recurrence was low. In addition to nodal status, subgroup classification was found to be an important factor affecting the risk of recurrence.
乳腺癌的复发风险不仅取决于治疗等因素,还取决于内在亚型。我们分析了局部、区域及全身复发的风险因素,评估了差异,并分析了不同分子亚型的复发风险。对1998年至2011年间在HSK医院或埃森中央医院接受手术及辅助治疗的3054例乳腺癌患者进行了分析。根据免疫组化参数,癌症被分为以下亚组:腔面A型、腔面B型(HER2阴性)、腔面B型(HER2阳性)、HER2阳性型和三阴性乳腺癌(TNBC)。67%的肿瘤被分类为腔面A型,13%为腔面B型(HER2阴性),6%为腔面B型(HER2阳性),3%为HER2阳性型,11%为三阴性乳腺癌。中位随访时间为6.6年后,出现100例局部复发(3.3%)、32例区域复发(1%)和248例远处复发(8%)。总体患者群体的5年无复发生存率为92%。多因素分析发现,阳性淋巴结状态、三阴性乳腺癌亚型和未接受放疗是所有复发形式的独立危险因素。年龄<50岁、肿瘤大小、腔面B型(HER2阴性)亚型和保乳治疗是局部复发的额外危险因素。与腔面A型亚型相比,所有其他亚型的全身复发风险更高;全身复发的额外危险因素是淋巴侵犯、未接受全身治疗和乳房切除术。总体而言,局部和区域复发风险较低。除淋巴结状态外,亚组分类是影响复发风险的一个重要因素。